FDA Approves Cemiplimab as First Adjuvant Immunotherapy for High Risk CSCC
The FDA has approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk for recurrence following surgery and radiation. This






